Bachem vs Eli Lilly vs Novo Nordisk and 1 More Revenue Comparison
Compare financial metrics side-by-side using real SEC EDGAR data
Revenue Comparison
Chart: Revenue Comparison. Values in USD billions. In Q2 2026: Bachem 0.1845, Eli Lilly 24.397, Novo Nordisk 12.196, Pfizer 16.583.
* Bachem reports semi-annually. Values are evenly split across both quarters within each half.
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, Bachem, Eli Lilly, Novo Nordisk, Pfizer.| Metric | Bachem | Eli Lilly | Novo Nordisk | Pfizer |
|---|---|---|---|---|
| Market Cap | $7.26B | $1.28T | $179.27B | $165.12B |
| Revenue | $369.00M | $24.40B | $12.20B | $16.58B |
| Cost of Revenue | $277.00M | $3.93B | $2.81B | $4.03B |
| Gross Profit | $92.00M | $20.46B | $9.39B | $12.55B |
| Operating Income | $61.00M | $8.61B | $3.54B | $3.67B |
| Net Income | $57.00M | $6.45B | $2.58B | $3.24B |
| R&D Expense | $7.00M | $4.25B | $3.06B | $3.02B |
| Earnings Per Share | $0.76 | $7.22 | $0.58 | $0.56 |
| Gross Margin | 25.0% | 83.9% | 77.0% | 75.7% |
| Operating Margin | 16.4% | 35.3% | 29.1% | 22.1% |
| Net Profit Margin | 15.4% | 26.4% | 21.1% | 19.6% |
| Free Cash Flow | $-63.00M | $8.22B | $4.33B | $4.80B |
| Cumulative Free Cash Flow | $76.00M | $117.88B | $111.72B | $361.51B |
| Operating Cash Flow | $118.00M | $11.40B | $6.35B | $5.38B |
| Cash & Equivalents | $58.00M | $4.88B | $6.80B | $1.82B |